APA (7th ed.) Citation

Fitz-Patrick, D., Sahgal, O., Fouché, L. F., Mitha, E., Malahleha, M., Gayed, J., . . . Kitchin, N. (2026). Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive. Infectious Diseases & Therapy, 1. https://doi.org/10.1007/s40121-026-01409-1

Chicago Style (17th ed.) Citation

Fitz-Patrick, David, et al. "Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive." Infectious Diseases & Therapy 2026: 1. https://doi.org/10.1007/s40121-026-01409-1.

MLA (9th ed.) Citation

Fitz-Patrick, David, et al. "Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive." Infectious Diseases & Therapy, 2026, p. 1, https://doi.org/10.1007/s40121-026-01409-1.